4-碘苯并[b]噻吩-2-羧酸甲酯 | 146137-85-1

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 4-碘苯并[b]噻吩-2-羧酸甲酯
• 中文别名: 4-碘苯并[B]噻吩-2-甲酸甲酯
• 英文名称: methyl 4-iodobenzo[b]thiophene-2-carboxylate
• 英文别名: methyl 4-iodo-1-benzothiophene-2-carboxylate
• CAS: 146137-85-1
• 化学式: C₁₀H₇IO₂S
• 分子量: 318.135
• InChiKey: UGNPKTSBZTYSKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8℃，请避光、干燥密闭保存。

反应信息

• 作为反应物：
  描述：

  4-碘苯并[b]噻吩-2-羧酸甲酯 在 manganese(IV) oxide 、 四(三苯基膦)钯 、 二异丁基氢化铝 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 13.0h， 生成
  参考文献：
  名称：

  A benzo[ b ]thiophene-based selective type 4 S1P receptor agonist

  摘要：

  S1P receptors (S1PR1-5) are a group of GPCRs activated by a high affinity binding with S1P that have important roles in the regulation of the immune system. A potent S1PR agonist FTY720 is an immunomodulator used to treat multiple sclerosis and several 'second generation' drugs are under clinical development. Subtype-selective agonists have been reported for each S1PR isotype, some of which are used as pharmacological tools for functional studies. Here we report the discovery and initial characterization of compound 5c, a benzo[b]thiophene amino carboxylate which exhibits potent and selective agonist activity for S1PR4. Compound 5c has an EC50 = 200 nM as an agonist in GTP gamma S-35 binding assay for S1PR4 and exhibits no activity against S1PR1,2,3,5. We confirmed its potent activity and decent S1PR subtype selectivity using biochemical and cellular assays. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.11.050
• 作为产物：
  描述：

  间氟碘苯 在 三乙胺 、 lithium diisopropyl amide 作用下， 以 二甲基亚砜 为溶剂， 生成 4-碘苯并[b]噻吩-2-羧酸甲酯
  参考文献：
  名称：

  氟作为芳族金属中的邻位导向基团：取代苯并[b]噻吩-2-羧酸酯的两步制备

  摘要：

  已经开发了由芳基氟化物简单地两步合成B环取代的苯并[b]噻吩-2-羧酸酯的方法。该路线涉及对氟的邻位选择性锂化，然后进行甲酰化，随后在一次操作中用硫代乙醇酸酯置换氟并进行碱诱导的闭环。

  DOI：

  10.1016/s0040-4039(00)60806-7

文献信息

• Urokinase inhibitors
  申请人：Eisai Co., Ltd.

  公开号：US05340833A1

  公开（公告）日：1994-08-23

  Disclosed are benzothiophene and thienothiophene derivatives useful for inhibiting urokinase activity.

  揭示了对抑制尿激酶活性有用的苯并噻吩和噻吩噻吩衍生物。
• METHOD FOR PROMOTING PLANT GROWTH
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20150282482A1

  公开（公告）日：2015-10-08

  The present invention provides a method for promoting plant growth, which comprises treating a plant with a compound represented by the following Formula (1): provided that a method for promoting plant growth which comprises treating plants with a compound corresponding to any one of the following (1) to (8) is excluded: (1) Methyl 4-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (2) Methyl 5-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (3) Methyl 6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (4) Methyl 7-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (5) Ethyl 4-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (6) Ethyl 5-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (7) Ethyl 6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, and (8) Ethyl 7-(trifluoromethyl)benzo[b]thiophene-2-carboxylate.

  本发明提供了一种促进植物生长的方法，包括用下式表示的化合物处理植物： 只要排除用与以下任一化合物相对应的化合物处理植物的促进植物生长方法：(1) 甲基4-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(2) 甲基5-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(3) 甲基6-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(4) 甲基7-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(5) 乙基4-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(6) 乙基5-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(7) 乙基6-(三氟甲基)苯并[b]噻吩-2-羧酸酯，以及(8) 乙基7-(三氟甲基)苯并[b]噻吩-2-羧酸酯。
• Evaluation of Radiolabeled (Hetero)Aromatic Analogues of <i>N</i>-(2-diethylaminoethyl)-4-iodobenzamide for Imaging and Targeted Radionuclide Therapy of Melanoma
  作者：Jean-Michel Chezal、Janine Papon、Pierre Labarre、Claire Lartigue、Marie-Josephe Galmier、Caroline Decombat、Olivier Chavignon、Jean Maublant、Jean-Claude Teulade、Jean-Claude Madelmont、Nicole Moins

  DOI：10.1021/jm701424g

  日期：2008.6.1

  discovered. Targeted radionuclide therapy concentrates the effects on tumor cells, thereby increasing the efficacy and decreasing the morbidity of radiotherapy. In this context, analogues of N-(2-diethylaminoethyl)-4-iodobenzamide (BZA) are of interest. Various (hetero)aromatic analogues 5 of BZA were synthesized and radioiodinated with (125)I, and their biodistribution in melanoma-bearing mice was studied

  使用对黑素瘤组织具有特定亲和力的放射性碘化化合物的靶向放射性核素治疗是弥散性黑素瘤的一种有前途的治疗方法，但具有理想动力学特征的候选药物仍有待发现。靶向放射性核素疗法集中了对肿瘤细胞的作用，从而提高了疗效并降低了放射疗法的发病率。在这种情况下，N-（2-二乙基氨基乙基）-4-碘代苯甲酰胺（BZA）的类似物是令人关注的。合成了多种BZA的（杂）芳族类似物5并用（125）I进行了放射性碘标记，并在静脉注射后研究了它们在荷黑素瘤小鼠中的生物分布。大多数[（125）I] 5标记的化合物似乎与黑素瘤肿瘤特异性结合并且具有中到高亲和力。5h和5k这两种化合物，
• Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same
  申请人：Yi Kyu Yang

  公开号：US20100004466A1

  公开（公告）日：2010-01-07

  The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium/hydrogen exchanger NHE-I, improve the functional recovery of ischemia/reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty.

  本发明涉及苯并噻吩-2-羧酰基胍衍生物、其制备方法以及含有其的制药组合物。这些衍生物对钠/氢交换NHE-I具有强效的抑制作用，在离体缺血心脏模型中提高了缺血/再灌注所致的心脏损伤的功能恢复，并在体内缺血动物模型中显著减少心肌梗死面积，因此表现出优异的心脏保护作用。此外，这些衍生物通过对神经元细胞的保护作用和在体内缺血脑模型中显著减少脑梗死面积的能力，也能保护神经元和大脑。这些衍生物可有效用于预防和治疗缺血性心脏疾病，如心肌梗死、心律失常、心绞痛等，以及脑血管疾病，如脑卒中，并可用作心脏保护剂，用于接受再灌注治疗的患者，包括使用溶栓剂等化学药物或手术，如冠状动脉旁路移植术和经皮冠状动脉成形术。
• LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS
  申请人：Madelmont Jean-Claude

  公开号：US20100061928A1

  公开（公告）日：2010-03-11

  The present invention relates to the use of a compound of formula (I): in which R 1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R 2 and R 3 represent, independently of one another, a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.

  本发明涉及使用式（I）化合物：其中R1代表放射性核素，Ar代表芳香环，m为2到4的整数，R2和R3代表独立的氢原子，（C1-C6）烷基，（C1-C6）烯基或苯基，所述苯基选择自苯基，苄基，咪唑基，吡啶基，嘧啶基，吡嗪基，吲哚基，吲唑基，呋喃基和噻吩基，并且它们与药学上可接受的酸的加成盐，用于制备放射性药物组合物，用于诊断和/或治疗黑色素瘤。